Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma

Modern Pathology

Volumn 22, Issue 9, 2009, Pages 1176-1185

  Han, Bo ^a   Mehra, Rohit ^a   Suleman, Khalid ^a   Tomlins, Scott A ^a   Wang, Lei ^a   Singhal, Nishi ^a   Linetzky, Katherine A ^a   Palanisamy, Nallasivam ^a   Zhou, Ming ^b   Chinnaiyan, Arul M ^a   Shah, Rajal B ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ETS; Fluorescence in situ hybridization; Histologic variant; Prostate carcinoma; Rearrangement

Indexed keywords

TRANSCRIPTION ERG; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETV4; TRANSCRIPTION FACTOR ETV5; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENE FUSION; GENE REARRANGEMENT; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CARCINOMA;

AGED; CARCINOMA; CARRIER PROTEINS; CHROMOSOME ABERRATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69549135270     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.79     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
2. Che M, Grignon D. Pathology of prostate cancer. Cancer Metastasis Rev 2002;21:381-395.
3. Randolph TL, Amin MB, Ro JY, et al. Histologic variants of adenocarcinoma and other carcinomas of prostate: pathologic criteria and clinical significance. Mod Pathol 1997;10:612-619.
4. Grignon DJ. Unusual subtypes of prostate cancer. Mod Pathol 2004;17:316-327.
5. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648. (Pubitemid 41528150)
6. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-3400.
7. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80.
8. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-599. (Pubitemid 47206938)
9. Han B, Mehra R, Dhanasekaran SM, et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008;68:7629-7637.
10. Hermans KG, Bressers AA, van der Korput HA, et al. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 2008;68:3094-3098.
11. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007;20:538-544. (Pubitemid 46631996)
12. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008;68:3584-3590.
13. Tu JJ, Rohan S, Kao J, et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Mod Pathol 2007;20:921-928. (Pubitemid 47267823)
14. Rajput AB, Miller MA, De Luca A, et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007;60:1238-1243. (Pubitemid 350084545)
15. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006;66:8337-8341. (Pubitemid 44449140)
16. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263.
17. Demichelis F, Fal K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-4599. (Pubitemid 47037039)
18. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695. (Pubitemid 350249347)
19. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51. (Pubitemid 46026500)
20. Iljin K,Wolf M, Edgren H, et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006;66:10242-10246. (Pubitemid 44799738)
21. Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13:519-528. (Pubitemid 351763901)
22. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-2384.
23. Halvarsson B, Muller W, Planck M, et al. Phenotypic heterogeneity in hereditary non-polyposis colorectal cancer: identical germline mutations associated with variable tumour morphology and immunohistochemical expression. J Clin Pathol 2007;60:781-786. (Pubitemid 47056907)
24. Lakhani SR. The pathology of familial breast cancer: morphological aspects. Breast Cancer Res 1999;1:31-35. (Pubitemid 32223533)
25. Mosquera JM, Perner S, Demichelis F, et al. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. J Pathol 2007;212:91-101. (Pubitemid 46746294)
26. Mehra R, Han B, Tomlins SA, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007;67:7991-7995. (Pubitemid 47395131)
27. Han B, Mori I, Wang X, et al. Combined small-cell carcinoma of the stomach: p53 and K-ras gene mutational analysis supports a monoclonal origin of three histological components. Int J Exp Pathol 2005;86:213-218. (Pubitemid 41074386)
28. Makretsov N, He M, Hayes M, et al. A fluorescence in situ hybridization study of ETV6-NTRK3 fusion gene in secretory breast carcinoma. Genes Chromosomes Cancer 2004;40:152-157. (Pubitemid 38579884)
29. Mertz KD, Setlur SR, Dhanasekaran SM, et al. Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia 2007;9:200-206.
30. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-888. (Pubitemid 47165141)
31. Barry M, Perner S, Demichelis F, et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70:630-633. (Pubitemid 350030260)